120 related articles for article (PubMed ID: 17349798)
21. Does single intramuscular application of autologous conditioned plasma influence systemic circulating growth factors?
Schippinger G; Fankhauser F; Oettl K; Spirk S; Hofmann P
J Sports Sci Med; 2012; 11(3):551-6. PubMed ID: 24149367
[TBL] [Abstract][Full Text] [Related]
22. The effects of mechanical loading on tendons--an in vivo and in vitro model study.
Zhang J; Wang JH
PLoS One; 2013; 8(8):e71740. PubMed ID: 23977130
[TBL] [Abstract][Full Text] [Related]
23. A perspective on the role of estrogen in hormone-induced prostate carcinogenesis.
Bosland MC
Cancer Lett; 2013 Jun; 334(1):28-33. PubMed ID: 22939996
[TBL] [Abstract][Full Text] [Related]
24. Hormones and prostate carcinogenesis: Androgens and estrogens.
Bosland MC; Mahmoud AM
J Carcinog; 2011; 10():33. PubMed ID: 22279418
[TBL] [Abstract][Full Text] [Related]
25. Dietary fat, fiber, and carbohydrate intake and endogenous hormone levels in premenopausal women.
Cui X; Rosner B; Willett WC; Hankinson SE
Horm Cancer; 2010 Oct; 1(5):265-76. PubMed ID: 21761370
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the equine skeletal muscle transcriptome identifies novel functional responses to exercise training.
McGivney BA; McGettigan PA; Browne JA; Evans AC; Fonseca RG; Loftus BJ; Lohan A; MacHugh DE; Murphy BA; Katz LM; Hill EW
BMC Genomics; 2010 Jun; 11():398. PubMed ID: 20573200
[TBL] [Abstract][Full Text] [Related]
27. Salivary free insulin-like growth factor-i levels: effects of an acute physical exercise in athletes.
Antonelli G; Gatti R; Prearo M; De Palo EF
J Endocrinol Invest; 2009 Jan; 32(1):1-5. PubMed ID: 19337006
[TBL] [Abstract][Full Text] [Related]
28. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States.
Cohen J; Collins R; Darkes J; Gwartney D
J Int Soc Sports Nutr; 2007 Oct; 4():12. PubMed ID: 17931410
[TBL] [Abstract][Full Text] [Related]
29. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
Tentori L; Graziani G
Pharmacol Res; 2007 May; 55(5):359-69. PubMed ID: 17349798
[TBL] [Abstract][Full Text] [Related]
30. [Doping and urologic tumors].
Pinto F; Sacco E; Volpe A; Gardi M; Totaro A; Calarco A; Racioppi M; Gulino G; D'Addessi A; Bassi PF
Urologia; 2010; 77(2):92-9. PubMed ID: 20890867
[TBL] [Abstract][Full Text] [Related]
31. Use of hormones in doping and cancer risk.
De Santi M; Baldelli G; Brandi G; ;
Ann Ig; 2019; 31(6):590-594. PubMed ID: 31616903
[TBL] [Abstract][Full Text] [Related]
32. [Doping: effectiveness, consequences, prevention].
Guezennec CY
Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 1):33-41. PubMed ID: 11240405
[TBL] [Abstract][Full Text] [Related]
33. Doping in sport: effects, harm and misconceptions.
Birzniece V
Intern Med J; 2015 Mar; 45(3):239-48. PubMed ID: 25369881
[TBL] [Abstract][Full Text] [Related]
34. [Use of anabolic androgenic steroids, growth hormone and erythropoietin by patients in general practice].
Keld DB; Hahn T
Ugeskr Laeger; 2006 Sep; 168(37):3121-4. PubMed ID: 16999915
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
